SoftOx Solutions AS

SoftOx Solutions AS FCF/Debt

The Free Cash Flow to Debt Ratio of SoftOx Solutions AS (SOFTX.OL) as of Oct 28, 2026 is 125.46 %. In the previous year, Free Cash Flow to Debt Ratio was -24.12 % — a change of -620.14% (higher).

FCF/Debt

125.46 %

YoY

-620.14%

Last updated:

Free Cash Flow to Debt Ratio of SoftOx Solutions AS is 2024 125.46 % . Free Cash Flow to Debt Ratio of SoftOx Solutions AS was 2023 -24.12 % . It decreases by -620.14% higher compared to the previous year.

The SoftOx Solutions AS FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-819.17 NOK
Jan 1, 2019
-443.75 NOK
Jan 1, 2021
-1,443.58 NOK
Jan 1, 2022
-1,028.67 NOK
Jan 1, 2023
-24.12 NOK
Jan 1, 2024
125.46 NOK
The SoftOx Solutions AS FCF/Debt history
YEARFCF/DebtYoY
125.46 %-620.14%
-24.12 %-97.66%
-1,028.67 %-28.74%
-1,443.58 %+225.31%
-443.75 %-45.83%
-819.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SoftOx Solutions AS Stock analysis

What does SoftOx Solutions AS do? SoftOx Solutions AS develops infection control solutions for wounds, disinfection, and respiratory care, with products classified as medical devices or medicinal products. The company's portfolio includes SafeDes+, a hand disinfectant designed for irritated, compromised, and eczematous skin. Its business segments are Wounds, Disinfection, and Respiratory, each focusing on specific medical applications. The firm generates revenue through the sale of its products to healthcare providers and medical institutions within these segments. SoftOx Solutions AS operates through subsidiaries such as SoftOx Disinfection AS, SoftOx Defense Solutions AS, and SoftOx Denmark AS, which support the development and distribution of its product range. The company's products are targeted at healthcare facilities requiring specialized infection control solutions, including hospitals and clinics specializing in wound care, respiratory treatments, and disinfection protocols. Revenue is derived from the commercialization of SafeDes+ and other products within its medical device and medicinal product categories. The company's business model centers on research and product development, with a focus on creating solutions for specific medical needs. Its subsidiaries facilitate the operational structure, enabling the company to manage different aspects of product development and market distribution. Sales are driven by the demand for infection control solutions in healthcare settings, particularly for products addressing skin conditions and respiratory health. SoftOx Solutions AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SoftOx Solutions AS stock

Free Cash Flow to Debt Ratio of SoftOx Solutions AS is 125.46 % in 2024.

Free Cash Flow to Debt Ratio of SoftOx Solutions AS changed from -24.12 % to 125.46 %, representing a -620.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio SoftOx Solutions AS since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's SoftOx Solutions AS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SoftOx Solutions AS

All Key Metrics — SoftOx Solutions AS